Literature DB >> 28088598

Are the Current Guidelines for the Surgical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas Adequate? A Multi-Institutional Study.

Gregory C Wilson1, Shishir K Maithel2, David Bentrem3, Daniel E Abbott4, Sharon Weber4, Clifford Cho4, Robert C G Martin5, Charles R Scoggins5, Hong Jin Kim6, Nipun B Merchant7, David A Kooby2, Michael J Edwards1, Syed A Ahmad8.   

Abstract

BACKGROUND: Controversy persists regarding the management of patients with intraductal papillary mucinous neoplasms (IPMN). International consensus guidelines stratify patients into high-risk, worrisome, and low risk categories. STUDY
DESIGN: The medical records of 7 institutions were reviewed for patients who underwent surgical management of IPMN between 2000 and 2015.
RESULTS: There were 324 patients included in the analysis; 60.4% of patients had main-duct/mixed type, and 39.7% had branch-duct IPMN. The median cyst size was 2.65 cm, invasive cancer (IC) or high-grade dysplasia (HGD) was present in 42% (n = 136); 68.9% of patients with high-risk, 40.0% of patients with worrisome, and 24.6% of patients with low risk features exhibited HGD/IC. Multivariate analysis demonstrated that only 1 of 3 high-risk features and 2 of 7 worrisome features predicted the presence of HGD/IC. Positive predictive values for HGD/ IC in patients with obstructive jaundice and lymphadenopathy were 0.83 (95% CI 0.65 to 0.94) and 0.69 (95% CI 0.39 to 0.91), respectively. In the absence of high-risk features, HGD/IC was still present in 57.4% of patients with 2 or more worrisome features. Regression analysis demonstrated that each additional worrisome factor present was additive in predicting HGD/IC in a linear fashion (odds ratio 1.39; 95% CI 1.08 to 1.80; p < 0.01).
CONCLUSIONS: These data demonstrate that the current consensus guidelines for surgical resection of IPMN may not adequately stratify and identify patients at risk for having HGD or invasive cancer. Patients with multiple worrisome features, in the absence of high-risk factors, should be considered for resection.
Copyright © 2017 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28088598     DOI: 10.1016/j.jamcollsurg.2016.12.031

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  7 in total

Review 1.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.

Authors:  Annabelle L Fonseca; Kimberly Kirkwood; Michael P Kim; Anirban Maitra; Eugene J Koay
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

2.  Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions.

Authors:  Zachary E Stiles; Sheema Khan; Kurt T Patton; Meena Jaggi; Stephen W Behrman; Subhash C Chauhan
Journal:  HPB (Oxford)       Date:  2018-08-14       Impact factor: 3.647

Review 3.  Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?

Authors:  Nicole E Rich; Amit G Singal
Journal:  Hepatology       Date:  2022-01-18       Impact factor: 17.425

Review 4.  Cancer overdiagnosis: a biological challenge and clinical dilemma.

Authors:  Sudhir Srivastava; Eugene J Koay; Alexander D Borowsky; Angelo M De Marzo; Sharmistha Ghosh; Paul D Wagner; Barnett S Kramer
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

5.  Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study.

Authors:  Alessandra Pulvirenti; Georgios A Margonis; Vicente Morales-Oyarvide; Caitlin A McIntyre; Sharon A Lawrence; Debra A Goldman; Mithat Gonen; Matthew J Weiss; Cristina R Ferrone; Jin He; Murray F Brennan; John L Cameron; Keith D Lillemoe; T Peter Kingham; Vinod Balachandran; Motaz Qadan; Michael I D'Angelica; William R Jarnagin; Christopher L Wolfgang; Carlos Fernández-Del Castillo; Peter J Allen
Journal:  Ann Surg       Date:  2021-12-01       Impact factor: 13.787

6.  Evidence-Based Guidelines for Branch-Duct Intraductal Papillary Mucinous Neoplasm Management: Still a Lot of Room to Grow.

Authors:  Patricia C Conroy; Eric Nakakura
Journal:  JAMA Surg       Date:  2021-07-01       Impact factor: 16.681

7.  Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN).

Authors:  Yoshiki Fujiyama; Yusuke Kumamoto; Nobuyuki Nishizawa; Shuji Nakamoto; Hiroki Harada; Kazuko Yokota; Yoko Tanaka; Kazuharu Igarashi; Hironobu Oiki; Kosuke Okuwaki; Tomohisa Iwai; Sabine Kajita; Hiroyuki Takahashi; Hiroshi Tajima; Takashi Kaizu; Jiichiro Sasaki; Masahiko Watanabe; Keishi Yamashita
Journal:  Ann Surg Oncol       Date:  2020-03-06       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.